Purine analogue-based chemotherapy regimens for second-line therapy in patients with chronic lymphocytic leukemia

Seminars in Hematology

Volumn 43, Issue SUPPL. 2, 2006, Pages

  Lamanna, Nicole ^a   Weiss, Mark A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; MONOCLONAL ANTIBODY; PENTOSTATIN; PREDNISONE; PURINE DERIVATIVE; RITUXIMAB; STEROID; VINCRISTINE;

BONE MARROW SUPPRESSION; CANCER STAGING; CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG INHIBITION; DRUG POTENTIATION; DRUG UPTAKE; HUMAN; IMMUNE DEFICIENCY; INFECTION; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; REMISSION; REVIEW; THROMBOCYTOPENIA;

EID: 33644994705     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2005.12.009     Document Type: Article

References (45)

1. L.F. Diehl, L.H. Karnell, H.R. Menck The American College of Surgeons Commission on Cancer and the American Cancer Society The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia Cancer 86 1999 2684 2692
2. S. O'Brien, A. del Giglio, M. Keating Advances in the biology and treatment of B-cell chronic lymphocytic leukemia Blood 85 1995 307 318
3. J.A. Zwiebel, B.D. Cheson Chronic lymphocytic leukemia Staging and prognostic factors Semin Oncol 25 1998 42 59
4. H. Dohner, S. Stilgenbauer, A. Benner, E. Leupolt, A. Krober, L. Bullinger Genomic aberrations and survival in chronic lymphocytic leukemia N Engl J Med 343 2000 1910 1916
5. K.R. Rai, A. Sawitsky, E.P. Cronkite, A.D. Chanana, R.N. Levy, B.S. Pasternack Clinical staging of chronic lymphocytic leukemia Blood 46 1975 219 234
6. J.L. Binet, A. Auquier, G. Dighiero, C. Chastang, H. Piguet, J. Goasguen A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis Cancer 48 1981 198 206
7. G. Dighiero, K. Maloum, B. Desablens, B. Cazin, M. Navarro, R. Leblay French Cooperative Group on Chronic Lymphocytic Leukemia Chlorambucil in indolent chronic lymphocytic leukemia N Engl J Med 338 1998 1506 1514
8. The French Cooperative Group on Chronic Lymphocytic Leukemia Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A) Results of a randomized clinical trial on 612 patients Blood 75 1990 1414 1421
9. B.D. Cheson, J.M. Bennett, M. Grever, N. Kay, M.J. Keating, S. O'Brien National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia Revised guidelines for diagnosis and treatment Blood 87 1996 4990 4997
10. M.J. Keating, H. Kantarjian, M. Talpaz, J. Redman, C. Koller, B. Barlogie Fludarabine A new agent with major activity against chronic lymphocytic leukemia Blood 74 1989 19 25
11. K.R. Rai, B.L. Peterson, F.R. Appelbaum, J. Kolitz, L. Elias, L. Shepherd Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia N Engl J Med 343 2000 1750 1757
12. G.P. Summerfield, P.R. Taylor, P.J. Mounter, S.J. Proctor High-dose chlorambucil for the treatment of chronic lymphocytic leukaemia and low-grade non-Hodgkin's lymphoma Br J Haematol 116 2002 781 786
13. M. Leporrier, S. Chevret, B. Cazin, N. Boudjerra, P. Feugier, B. Desablens Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients Blood 98 2001 2319 2325
14. S. Johnson, A.G. Smith, H. Loffler, E. Osby, G. Juliusson, B. Emmerich The French Cooperative Group on CLL Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia Lancet 347 1996 1432 1438
15. T. Robak, J.Z. Blonski, M. Kasznicki, M. Blasinska-Morawiec, E. Krykowski, A. Dmoszynska Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia Report of a prospective, randomized, multicenter trial Blood 96 2000 2723 2729
16. T. Robak The role of nucleoside analogues in the treatment of chronic lymphocytic leukemia - Lessons learned from prospective randomized trials Leuk Lymphoma 43 2002 537 548
17. R.N. Brogden, E.M. Sorkin Pentostatin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders Drugs 46 1993 652 677
18. E.R. Giblett, J.E. Anderson, F. Cohen, B. Pollara, H.J. Meuwissen Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity Lancet 2 1972 1067 1069
19. S.A. Johnson, W. Thomas Therapeutic potential of purine analogue combinations in the treatment of lymphoid malignancies Hematol Oncol 18 2000 141 153
20. M.R. Grever, K.J. Kopecky, C.A. Coltman, J.C. Files, B.R. Greenberg, J.J. Hutton Fludarabine monophosphate A potentially useful agent in chronic lymphocytic leukemia Nouv Rev Fr Hematol 30 1988 457 459
21. S. O'Brien, H. Kantarjian, M. Beran, T. Smith, C. Koller, E. Estey Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment Blood 82 1993 1695 1700
22. M.J. Keating, S. O'Brien, S. Lerner, C. Koller, M. Beran, L.E. Robertson Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy Blood 92 1998 1165 1171
23. M.J. Keating, H. Kantarjian, S. O'Brien, C. Koller, M. Talpaz, J. Schachner Fludarabine A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia J Clin Oncol 9 1991 44 49
24. L. Elias, D. Stock-Novack, D.R. Head, M.R. Grever, J.K. Weick, R.A. Chapman A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia A Southwest Oncology Group study Leukemia 7 1993 361 365
25. M. Weiss, T. Spiess, E. Berman, S. Kempin Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia Leukemia 8 1994 1290 1293
26. S.M. O'Brien, H.M. Kantarjian, J. Cortes, M. Beran, C.A. Koller, F.J. Giles Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia J Clin Oncol 19 2001 1414 1420
27. W. Wierda, S. O'Brien, S. Wen, S. Faderl, G. Garcia-Manero, D. Thomas Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia J Clin Oncol 23 2005 4070 4078
28. I.W. Flinn, J.C. Byrd, C. Morrison, J. Jamison, L.F. Diehl, T. Murphy Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies Blood 96 2000 71 75
29. M.A. Weiss, M. Glenn, P. Maslak, Z. Rahman, A. Noy, A. Zelenetz Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy Leukemia 14 2000 1577 1582
30. N. Lamanna Advances in the treatment of chronic lymphocytic leukemia Curr Oncol Rep 7 2005 333 338
31. T. Robak, J.Z. Blonski, M. Kasznicki, J. Gora-Tybor, J. Dwilewicz-Trojaczek, B. Stella-Holowiecka Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia Hematol J 3 2002 244 250
32. A. Saven, S. Emanuele, M. Kosty, J. Koziol, D. Ellison, L. Piro 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma Blood 86 1995 1710 1716
33. M. Montillo, A. Tedeschi, S. O'Brien, F. Di Raimondo, S. Lerner, A. Ferrajoli Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia Cancer 97 2003 114 120
34. M.R. Grever, M.F. Siaw, W.F. Jacob, J.A. Neidhart, J.S. Miser, M.S. Coleman The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoproliferative malignancy Blood 57 1981 406 417
35. R.O. Dillman, A.L. Yu, C.N. Qiao Repeated pentostatin (2′deoxycoformycin)-induced remissions in a patient with advanced chronic lymphocytic leukemia West J Med 148 1988 334 337
36. R.O. Dillman, R. Mick, O.R. McIntyre Pentostatin in chronic lymphocytic leukemia A phase II trial of Cancer and Leukemia Group B J Clin Oncol 7 1989 433 438
37. A.D. Ho, J. Thaler, P. Stryckmans, B. Coiffier, M. Luciani, P. Sonneveld Pentostatin in refractory chronic lymphocytic leukemia A phase II trial of the European Organization for Research and Treatment of Cancer J Natl Cancer Inst 82 1990 1416 1420
38. S.A. Johnson, D. Catovsky, J.A. Child, A.C. Newland, D.W. Milligan, R. Janmohamed Phase I/II evaluation of pentostatin (2′-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia Invest New Drugs 16 1998 155 160
39. J.B. Johnston, L. Verburg, T. Shore, M. Williams, L.G. Israels, A. Begleiter Combination therapy with nucleoside analogues and alkylating agents Leukemia 8 suppl 1 1994 S140 S143
40. A.S. Spiers, D. Moore, P.A. Cassileth, D.P. Harrington, F.J. Cummings, R.S. Neiman Remissions in hairy-cell leukemia with pentostatin (2′-deoxycoformycin) N Engl J Med 316 1987 825 830
41. M.R. Grever, E. Bisaccia, D.A. Scarborough, E.N. Metz, J.A. Neidhart An investigation of 2′-deoxycoformycin in the treatment of cutaneous T-cell lymphoma Blood 61 1983 279 282
42. M.M. Oken, S. Lee, N.E. Kay, W. Knospe, P.A. Cassileth Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia A phase I/II study by the Eastern Cooperative Oncology Group study E1488 Leuk Lymphoma 45 2004 79 84
43. J.K. Waselenko, M.R. Grever, M. Beer, M.A. Lucas, J.C. Byrd Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia Semin Oncol 27 2000 44 51
44. M.A. Weiss, P.G. Maslak, J.G. Jurcic, D.A. Schenberg, T.B. Aliff, N. Lamanna Pentostatin and cyclophosphamide An effective new regimen in previously treated patients with chronic lymphocytic leukemia J Clin Oncol 21 2003 1278 1284
45. B.L. Abbott Advances in the diagnosis and treatment of chronic lymphocytic leukemia Hematol Oncol 23 2005 34 40